Suppr超能文献

缓解-复发型多发性硬化症的疾病修正疗法。

Disease-modifying therapies in relapsing-remitting multiple sclerosis.

机构信息

Department of Medicine, Metropolitan Hospital, Av. Mariana de Jesús Oe8 y Occidental, 170125, Quito, Ecuador.

出版信息

Neuropsychiatr Dis Treat. 2010 Sep 7;6:365-73. doi: 10.2147/ndt.s11079.

Abstract

CLINICAL QUESTION

What is the best current disease-modifying therapy for relapsing-remitting multiple sclerosis?

RESULTS

The evidence shows that the most effective disease-modifying therapy for delaying short- to medium-term disability progression, prevention of relapses, reducing the area and activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, high-frequency subcutaneous interferon-β1a 44 μg three times per week.

IMPLEMENTATION

The pitfalls in treatment of MS can be avoided by remembering the following points: The most effective therapy to prevent or delay the appearance of permanent neurological disability with the fewest side effects should be chosen, and treatment should not be delayed.Adherence to treatment should be monitored closely, and needs comprehensive patient information and education to establish long-term adherence, which is a critical determinant of long-term outcome.The correct approach to the disease includes disease management, symptom management, and patient management. A combination of tools is necessary to ease the various symptoms, which fall into three broad categories, i.e. rehabilitation, pharmacological, and procedural.It is important to understand that no treatment modality should be used alone, unless it is in itself sufficient to remedy the particular symptom/problem.

摘要

临床问题

哪种疾病修正疗法对缓解-复发型多发性硬化最有效?

结果

有证据表明,最有效的疾病修正疗法是每周三次皮下注射高剂量、高频率的干扰素-β1a44μg,能延缓中短期残疾进展,预防复发,减少磁共振成像上的病灶面积和活跃度,且副作用最小。

实施

治疗多发性硬化症时,要谨记以下几点,以避免出现治疗失误:应选择最有效的疗法来预防或延迟永久性神经功能障碍的出现,且副作用最小;不应延迟治疗;应密切监测治疗依从性,需要全面的患者信息和教育,以建立长期的依从性,这是长期结果的关键决定因素;疾病管理、症状管理和患者管理都属于正确的疾病处理方式;需要使用一系列工具来缓解各种症状,这些症状分为康复、药理学和程序三大类;重要的是要明白,除非某种治疗方法本身足以解决特定的症状/问题,否则不应单独使用任何治疗方法。

相似文献

1
Disease-modifying therapies in relapsing-remitting multiple sclerosis.
Neuropsychiatr Dis Treat. 2010 Sep 7;6:365-73. doi: 10.2147/ndt.s11079.
3
Teriflunomide for multiple sclerosis.
Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3.
4
[Immunomodulatory therapy in multiple sclerosis].
Ideggyogy Sz. 2004 Nov 20;57(11-12):401-16.
6
Rituximab for relapsing-remitting multiple sclerosis.
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
7
Alemtuzumab for multiple sclerosis.
Cochrane Database Syst Rev. 2016 Apr 15;4(4):CD011203. doi: 10.1002/14651858.CD011203.pub2.
8
Mitoxantrone: a review of its use in multiple sclerosis.
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.

引用本文的文献

3
Stress as provoking factor for the first and repeated multiple sclerosis seizures.
Mater Sociomed. 2012;24(3):142-7. doi: 10.5455/msm.2012.24.142-147.
4
The evidence for hypoperfusion as a factor in multiple sclerosis lesion development.
Mult Scler Int. 2013;2013:598093. doi: 10.1155/2013/598093. Epub 2013 Apr 4.

本文引用的文献

1
Mitoxantrone for multiple sclerosis.
Cochrane Database Syst Rev. 2013 May 31;2013(5):CD002127. doi: 10.1002/14651858.CD002127.pub3.
3
The symptomatic management of multiple sclerosis.
Ann Indian Acad Neurol. 2009 Oct;12(4):291-5. doi: 10.4103/0972-2327.58278.
4
Combination therapy in multiple sclerosis.
Lancet Neurol. 2010 Mar;9(3):299-308. doi: 10.1016/S1474-4422(10)70007-7.
5
Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Mult Scler. 2010 May;16(5):588-96. doi: 10.1177/1352458509360549. Epub 2010 Feb 18.
7
PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018.
8
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Lancet Neurol. 2010 Mar;9(3):264-72. doi: 10.1016/S1474-4422(10)70006-5. Epub 2010 Jan 29.
10
The prevalence of multiple sclerosis in 3 US communities.
Prev Chronic Dis. 2010 Jan;7(1):A12. Epub 2009 Dec 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验